Opsonix launches with $8 million Series A to develop pathogen-extracting therapy for sepsis and other blood-borne infectious diseases
The company’s sepsis therapy has the potential to be used not only in combination with existing antibiotics, but also to treat patients when conventional therapeutic options are not available.
Opsonix has announced the company’s launch with an $8 million Series A financing to develop a pathogen-extracting therapy designed to remove infectious pathogens and toxins from circulating blood. This treatment potentially offers a new broad-spectrum approach to treat blood-borne infectious diseases, including sepsis. Opsonix will use the proceeds from the financing to advance the development of its extracorporeal pathogen-extracting therapy. The Series A financing was led by Baxter Ventures, alongside of investment by private investor Hansjörg Wyss.
Opsonix’s core technology is based on proprietary pathogen-capture proteins. Its lead molecule is a recombinant human protein derived from mannose binding lectin (MBL) fused to the Fc region of human immunoglobulin (FcMBL). When Opsonix’s FcMBL is attached to the membrane of a dialyzer-type device, it can remove a broad range of bacteria, fungi, parasites, viruses, and toxins responsible for initiating the sepsis cascade, including antibiotic-resistant organisms. Opsonix’s pathogen-extracting therapy has been designed to work in synergy with conventional antibiotic treatments.
“Opsonix’s pathogen-extracting therapy provides a novel therapeutic solution leveraging the broad binding activities of a natural human protein that may rapidly remove sepsis-causing pathogens - and the toxins they release - from a patient’s blood,” said Eric Devroe, Founder and CEO of Opsonix. “With our FcMBL-based pathogen-extracting therapy, treatment of blood-borne infectious disease can be initiated earlier in the course of infection, when it is most needed, without having to wait to identify the disease-causing pathogen. With the strong support of our investors and a compelling body of evidence developed by our scientific founders, Opsonix will move forward expeditiously with preclinical studies to advance our pathogen-extracting therapy.”
Opsonix’s pathogen-capture proteins are engineered versions of human blood opsonins — molecular components of the innate immune system that help to clear pathogens and the toxins they release. The company develops therapeutic products by applying recombinant protein engineering to harness the unique binding properties of opsonins that enable them to clear a broad range of infectious microbes and toxic components from blood, which can stimulate the inflammatory cascade that leads to sepsis.
In studies conducted and published by Opsonix’s scientific founders at Harvard University’s Wyss Institute for Biologically Inspired Engineering, FcMBL-based pathogen-extracting therapies have been shown to work in synergy with conventional antibiotics, as well as to clear blood of antibiotic-resistant organisms. Hence, Opsonix’s sepsis therapy has the potential to be used not only in combination with existing antibiotics, but also to treat patients when conventional therapeutic options are not available.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance